Research and Markets: Global Preimplantation Genetic Diagnosis (PGD) Market 2014-2018 - Growing Opportunity for Direct-to-Consumer Genetic Testing

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/c49z3s/global) has announced the addition of the "Global Preimplantation Genetic Diagnosis (PGD) Market 2014-2018" report to their offering.

This report covers the present scenario and the growth prospects of the Global Preimplantation Genetic Diagnosis market for the period 2014-2018. To calculate the market size, the report considers revenue generated from sales of PGD services and products including kits and instruments used for PGD.

Preimplantation genetic diagnosis (PGD) testing involves the identification of genetic defects in embryos. It is performed to identify single gene disorders such as Sickle Cell Anemia, Cystic Fibrosis, Huntington's Disease, Hemophilia, Marfan's Disease, Thalassemia, Muscular Dystrophy, Tay Sachs, and Spinal Muscular Atrophy.

PGD tests are generally carried out in cases of a known genetic defect, or in late age pregnancy, or in patients with a history of repeated miscarriages. PCR, FISH, CGH, and SNP are some of the common technologies used in PGD testing with PCR the most widely used. FISH technology is beneficial in the determination of chromosomal abnormalities, X-linked diseases, and aneuploidy screening. CGH and SNP are advanced technologies, which have high accuracy in screening and diagnosis.

One of the major trends in the market is the growing opportunity for direct-to-consumer genetic testing. The increasing awareness of genetic disorders supports the use of DTC genetic testing, which allows users to perform genetic testing at home.

According to the report, one of the major factors driving the market is the increasing rate of infertility in both men and women as a result of several factors such as late-age pregnancy, widespread obesity, drug abuse, and excessive use of alcohol.

Further, the report states that one of the major challenges in the market is the high cost of PGD. Most of the ART are not covered by any insurance, thus, every individual who needs the service may not be able to afford it.

Key Vendors

  • Genesis Genetics
  • Laboratory Corporation of America
  • Reproductive Genetics Institute
  • Reprogenetics

For more information visit http://www.researchandmarkets.com/research/c49z3s/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Diagnostics

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Diagnostics